Outcomes and cost of medical and surgical treatments of pilonidal disease: A single institution's 10-year review.
Journal
Surgery open science
ISSN: 2589-8450
Titre abrégé: Surg Open Sci
Pays: United States
ID NLM: 101768812
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
24
10
2021
revised:
18
03
2022
accepted:
24
03
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
2
6
2022
Statut:
epublish
Résumé
Pilonidal disease is a chronic inflammatory skin disorder typically located in the gluteal cleft. Treatment varies from antibiotic therapy to extensive surgical resection and reconstruction; however, complications and recurrence are common. To understand risk factors, outcomes, and costs associated with various treatments, we performed a retrospective chart review of all patients treated for pilonidal disease at a single health care system from 2008 to 2018. Patients with an ICD diagnosis code associated with pilonidal disease were identified. Charts were reviewed for demographic, clinical, and cost information related to pilonidal disease encounters. Data were analyzed for risk of recurrence by Cox proportional hazards regression and economic burden by Wilcoxon signed-rank test. During the study time frame, 513 patients were diagnosed with pilonidal disease. Primary treatment included 108 patients (21%) with wide excision, 167 (32%) with antibiotics alone, 79 (15%) with incision and drainage, and 109 (21%) with incision and drainage plus antibiotics. The rate of recurrence following antibiotic therapy, incision and drainage, or wide excision was 36.7%, 35.9%, and 21.3%, respectively. Sex, body mass index, obesity, or hidradenitis suppurativa was not associated with recurrence; however, smokers who underwent incision and drainage had a higher risk of recurrence (P < .0001). The median cost of each primary treatment was $3,093 for excision, $607 for incision and drainage, $281 antibiotics alone, and $686 for incision and drainage plus antibiotics. Pilonidal disease presents with a high degree of heterogeneity and is often managed primarily with antibiotics, incision and drainage, or surgical excision. Risk of recurrence was less in patients who underwent wide excision; however, these patients had higher overall cost compared to patients that had nonoperative management. Level III.
Sections du résumé
Background
UNASSIGNED
Pilonidal disease is a chronic inflammatory skin disorder typically located in the gluteal cleft. Treatment varies from antibiotic therapy to extensive surgical resection and reconstruction; however, complications and recurrence are common. To understand risk factors, outcomes, and costs associated with various treatments, we performed a retrospective chart review of all patients treated for pilonidal disease at a single health care system from 2008 to 2018.
Methods
UNASSIGNED
Patients with an ICD diagnosis code associated with pilonidal disease were identified. Charts were reviewed for demographic, clinical, and cost information related to pilonidal disease encounters. Data were analyzed for risk of recurrence by Cox proportional hazards regression and economic burden by Wilcoxon signed-rank test.
Results
UNASSIGNED
During the study time frame, 513 patients were diagnosed with pilonidal disease. Primary treatment included 108 patients (21%) with wide excision, 167 (32%) with antibiotics alone, 79 (15%) with incision and drainage, and 109 (21%) with incision and drainage plus antibiotics. The rate of recurrence following antibiotic therapy, incision and drainage, or wide excision was 36.7%, 35.9%, and 21.3%, respectively. Sex, body mass index, obesity, or hidradenitis suppurativa was not associated with recurrence; however, smokers who underwent incision and drainage had a higher risk of recurrence (P < .0001). The median cost of each primary treatment was $3,093 for excision, $607 for incision and drainage, $281 antibiotics alone, and $686 for incision and drainage plus antibiotics.
Conclusion
UNASSIGNED
Pilonidal disease presents with a high degree of heterogeneity and is often managed primarily with antibiotics, incision and drainage, or surgical excision. Risk of recurrence was less in patients who underwent wide excision; however, these patients had higher overall cost compared to patients that had nonoperative management.
Level of evidence
UNASSIGNED
Level III.
Identifiants
pubmed: 35647503
doi: 10.1016/j.sopen.2022.03.009
pii: S2589-8450(22)00017-3
pmc: PMC9136335
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-45Informations de copyright
© 2022 The Authors.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Surg Res. 2016 Jul;204(1):55-60
pubmed: 27451868
Eur J Surg. 1999 Apr;165(4):339-42
pubmed: 10365835
Lasers Med Sci. 2016 Jul;31(5):857-62
pubmed: 27003897
Sci Rep. 2018 Feb 15;8(1):3058
pubmed: 29449548
J Pediatr Surg. 2009 Jan;44(1):282-5
pubmed: 19159757
APMIS. 1995 Apr;103(4):267-72
pubmed: 7542011
J Dtsch Dermatol Ges. 2013 Oct;11(10):1001-5
pubmed: 23945165
Dermatol Surg. 2010;36(1):88-91
pubmed: 20002644
World J Surg. 2005 Apr;29(4):469-71
pubmed: 15770382
Dis Colon Rectum. 2000 Aug;43(8):1146-56
pubmed: 10950015
J Pediatr Surg. 2019 Nov;54(11):2210-2221
pubmed: 30948198
J Eur Acad Dermatol Venereol. 2009 Aug;23(8):883-6
pubmed: 19586514
J Surg Res. 2018 Dec;232:430-436
pubmed: 30463753